MHRA-102514-PIP01-26-M01 (update)

Key Facts

Active Substance
Active Substance:
  • Concentrate of proteolytic enzyme enriched in in bromelain
Invented Name
Nexobrid
PIP Number MHRA-102514-PIP01-26-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Powder and gel for gel
Therapeutic area
Therapeutic area:
  • Dermatology
Conditions / Indications
Conditions / Indications:
  • Treatment of burns.
Route(s) of administration
Route(s) of administration:
  • Cutaneous use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance Check Procedure Number
Compliance procedure number
MHRA-102514-PIP01-26-M01-C1

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Concentrate of proteolytic enzyme enriched in in bromelain.pdf
Published Date 23/07/2026